Vimarsana
Biggest News Aggregation in the World

Page 19 - Boxed Warning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Boxed Warning Today - Breaking & Trending Today

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive - Vimarsana News

ZILBRYSQ® (zilucoplan) Is Now Commercially Available in the U.S. for the Treatment of Generalized Myasthenia Gravis (gMG) in Adult Patients Who Are Anti-Acetylcholine Receptor (AChR) Antibody Positive

ZILBRYSQ® is now commercially available by prescription in the United States and dispensed by UCB's selected exclusive specialty pharmacy PANTHERx® Rare Pharmacy.ZILBRYSQ is FDA-approved as the...

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 - Vimarsana News

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PTWALTHAM, Mass., Jan. 03, 2024 -- Ardelyx, Inc. , a biopharmaceutical company founded with a mission to discover, develop and...

Welireg Approved for Advanced Renal Cell Carcinoma - Renal and Urology News - Vimarsana News

Welireg Approved for Advanced Renal Cell Carcinoma - Renal and Urology News

The FDA has approved Welireg (belzutifan) for the treatment of adult patients with advanced RCC following a PD-1 or PD-L1 inhibitor and a VEGF-TKI.

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 - Ardelyx (NASDAQ:ARDX) - Vimarsana News

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8 - Ardelyx (NASDAQ:ARDX)

WALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet

Jylamvo, an FDA-Approved Oral Solution Formulation of Methotrexate, Now Available - Vimarsana News

Jylamvo, an FDA-Approved Oral Solution Formulation of Methotrexate, Now Available

Jylamvo, an FDA-approved oral solution formulation of methotrexate, is now available from Shorla Oncology and Eversana.